The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Graph AI
AI platform automating drug safety and pharmacovigilance workflows for life sciences companies.
What they do
Graph AI applies explainable AI to pharmacovigilance, automating safety case processing and signal detection for drugmakers. In September 2026 it raised a $13.3M Series A led by Insight Partners with Bessemer Venture Partners.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Pharmacovigilance AI
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Pleasanton, United States
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $13M raised
Notable investors: Insight Partners, Bessemer Venture Partners.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
The Great Directory Rollup: How H1 Is Building the Single Source of Truth for Provider Networks
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Transporter-Independent Pharmacology and the Orphan PRV Playbook
Dr. Dereck Mush, MD, MBA